<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00686257</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-6060</org_study_id>
    <nct_id>NCT00686257</nct_id>
  </id_info>
  <brief_title>Evaluation Of The Total Face Mask For Emergency Application In Acute Respiratory Failure</brief_title>
  <official_title>Evaluation Of The Total Face Mask For Emergency Application In Acute Respiratory Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rhode Island Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the Total Face Mask™ (Respironics, Inc., Pittsburgh,
      PA) (covering whole face) and the standard oronasal facemask (covering nose and mouth) for
      the emergency treatment of patients with acute respiratory failure with the machine blowing
      air into the mask placed on the face (noninvasive positive pressure ventilation) (NPPV).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite its demonstrated efficacy in treating selected patients with acute respiratory
      failure, the application of NPPV is still plagued by a substantial failure rate, ranging from
      below 10% to above 40%. Mask intolerance ranks as one of the most common causes of failure.
      This is related to ill-fitting masks, mask discomfort (despite a properly fitted mask),
      excessively tightened straps, excessive air leaks around the mask or through the mouth, and
      claustrophobia.

      The most commonly used masks in the acute care setting are either oronasal masks that cover
      the nose and mouth, or nasal masks that cover the nose alone. Both mask types usually consist
      of clear plastic dome-shaped mask with a soft silicon gasket to create an air seal with the
      skin. While this approach is usually successful, it may lead to patient discomfort and/or an
      air leak secondary to the difficulty in creating an effective seal over the bridge of the
      nose and over mobile structures such as the mandible. The Total Face Mask ™ (Respironics,
      Inc., Pittsburgh, PA) uses a different approach to avoid some of these limitations.
      Considerably larger than a standard oronasal mask, it covers the entire face and creates an
      air seal using a silicon gasket around the parameter of the face. In this way, gasket
      pressure is more evenly distributed, and discomfort over the bridge of the nose or chin is
      eliminated, and air leaking reduced. In addition, because one mask size fits virtually all
      patients, the Total Face Mask ™ facilitates the fitting process and permits more rapid
      initiation of ventilatory assistance. Clinical experience to date suggests that
      claustrophobia is not a common problem with the Total Face Mask ™ despite its size, and that
      its contribution to dead space is comparable to that of most oronasal masks.

      The following protocol aims to compare use of the Total Face Mask ™ to the Comfort Full
      oronasal mask (also by Respironics, Inc., Pittsburgh, PA)or RT040 oronasal mask
      (Fisher&amp;Paykel Inc., Wellington, NZ) in the acute care setting for patients meeting standard
      indications for NPPV.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mask Comfort (as Determined by the Visual Analog Scores 1 Being Least, 10 Being Most)</measure>
    <time_frame>During the first 3 hours of recruitment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time Required for Mask Placement</measure>
    <time_frame>at the initiation of NPPV</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early NPPV Discontinuation Rate</measure>
    <time_frame>During hospitalization period (after recruitment into the study)</time_frame>
    <description>defined as the inability of the patient to be maintained on NPPV using the assigned mask while there was still an indication for ventilatory support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Vital Signs</measure>
    <time_frame>during the first 24 hours of the study</time_frame>
    <description>At initiation;30 minutes, 1 hour, 3 hours and 24 hours after NPPV initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Gas Exchange</measure>
    <time_frame>during the first 24 hours of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Length of Time Requiring NPPV</measure>
    <time_frame>during hospitalization (after recruitment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea</measure>
    <time_frame>During the first 3 hours of recruitment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>during hospitalization (after recruitment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital Mortality Rate</measure>
    <time_frame>during hospitalization (after recruitment)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Acute Respiratory Insufficiency</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving NPPV by the 'Total Face Mask'</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving NPPV by 'standard oronasal mask'</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Total face mask (interface for NPPV)</intervention_name>
    <description>NPPV is applied by this mask, as long as NPPV is received.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>cephalic mask</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Comfort full or RT040 oronasal mask (interface for NPPV)</intervention_name>
    <description>NPPV is applied by one of these masks (Comfort full or RT040 masks used at Rhode Island Hospital and Tufts Medical Center respectively), as long as NPPV is received.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Full face mask</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt;18

          -  Either A or B

        A. Clinical Criteria: Moderate to severe respiratory distress as evidenced by tachypnea,
        use of accessory muscles for breathing, or abdominal paradox.

        B. Blood Gas and Physiologic Criteria: Gas exchange abnormalities including PaCO2&gt;45 with a
        pH&lt;7.35, or a PaO2/FiO2 ratio&lt;200.

        Exclusion Criteria:

          -  The need for immediate intubation

          -  Medical instability such as hypotensive shock, uncontrolled cardiac ischemia or
             arrythmias, unstable myocardial infarction, uncontrolled upper gastrointestinal
             bleeding

          -  Agitation or uncooperativeness, unresponsive to small doses of sedatives

          -  Excretions or inability to protect the airway

          -  Inability to fit the mask

          -  Facial trauma

          -  Upper airway obstruction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aylin Ozsancak, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Research Fellow</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicholas S. Hill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chair of Pulmonary, Critical Care and Sleep Division</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samy Sidhom, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Fellow</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ozsancak A, Sidhom SS, Liesching TN, Howard W, Hill NS. Evaluation of the total face mask for noninvasive ventilation to treat acute respiratory failure. Chest. 2011 May;139(5):1034-1041. doi: 10.1378/chest.10-1905. Epub 2011 Feb 17.</citation>
    <PMID>21330385</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2008</study_first_submitted>
  <study_first_submitted_qc>May 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2008</study_first_posted>
  <results_first_submitted>May 30, 2012</results_first_submitted>
  <results_first_submitted_qc>July 24, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 27, 2012</results_first_posted>
  <last_update_submitted>July 24, 2012</last_update_submitted>
  <last_update_submitted_qc>July 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute respiratory insufficiency</keyword>
  <keyword>noninvasive ventilation</keyword>
  <keyword>oronasal face mask</keyword>
  <keyword>total face mask</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Total Face Mask</title>
          <description>Patients receiving NPPV by the 'Total Face Mask' or standard face mask controls</description>
        </group>
        <group group_id="P2">
          <title>Standard Face Mask Controls</title>
          <description>Patients receiving NPPV by 'standard oronasal mask'</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Total Face Mask</title>
          <description>Patients receiving NPPV by the 'Total Face Mask' or standard face mask controls</description>
        </group>
        <group group_id="B2">
          <title>Standard Face Mask Controls</title>
          <description>Patients receiving NPPV by 'standard oronasal mask'</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.4" spread="15"/>
                    <measurement group_id="B2" value="62.6" spread="17"/>
                    <measurement group_id="B3" value="62.9" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mask Comfort (as Determined by the Visual Analog Scores 1 Being Least, 10 Being Most)</title>
        <time_frame>During the first 3 hours of recruitment</time_frame>
        <population>By power analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Received standard face mask</description>
          </group>
          <group group_id="O2">
            <title>Total Face Mask</title>
            <description>Received Total Face Mask</description>
          </group>
        </group_list>
        <measure>
          <title>Mask Comfort (as Determined by the Visual Analog Scores 1 Being Least, 10 Being Most)</title>
          <population>By power analysis</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="0.6"/>
                    <measurement group_id="O2" value="3.3" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time Required for Mask Placement</title>
        <time_frame>at the initiation of NPPV</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Early NPPV Discontinuation Rate</title>
        <description>defined as the inability of the patient to be maintained on NPPV using the assigned mask while there was still an indication for ventilatory support</description>
        <time_frame>During hospitalization period (after recruitment into the study)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Vital Signs</title>
        <description>At initiation;30 minutes, 1 hour, 3 hours and 24 hours after NPPV initiation</description>
        <time_frame>during the first 24 hours of the study</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Gas Exchange</title>
        <time_frame>during the first 24 hours of the study</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Length of Time Requiring NPPV</title>
        <time_frame>during hospitalization (after recruitment)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dyspnea</title>
        <time_frame>During the first 3 hours of recruitment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospital Stay</title>
        <time_frame>during hospitalization (after recruitment)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-hospital Mortality Rate</title>
        <time_frame>during hospitalization (after recruitment)</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Total Face Mask</title>
          <description>Patients receiving NPPV by the 'Total Face Mask' or standard face mask controls</description>
        </group>
        <group group_id="E2">
          <title>Standard Face Mask Controls</title>
          <description>Patients receiving NPPV by 'standard oronasal mask'</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Claustrophobia</sub_title>
                <description>Claustrophobia in 4 control patients and 6 Total Face mask patients</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Could not blind subjects or investigators</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Nicholas Hill MD</name_or_title>
      <organization>Tufts Medical Center</organization>
      <phone>617-636-4288</phone>
      <email>nhill@tuftsmedicalcenter.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

